Table 3.

Impact of risk factors in different time periods after alloHCT

Time-period/population	0–2 years, all patients		2–10 years, 2-year LM population		5–10 years, 5-year LM population
Risk factor	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Patient sex
Male	1		1		1
Female	0.9 (0.9–1.0)	0.2	0.9 (0.7–1.0)	0.1	0.7 (0.5–1.0)	0.04
Age at alloHCT (per decade)	1.1 (1.1–1.2)	<0.001	1.2 (1.1–1.3)	<0.001	1.3 (1.1–1.6)	0.001
Year of alloHCT (per 5 years)	0.8 (0.8–0.9)	<0.001	1.2 (1.0–1.4)	0.02	1.4 (1.0–2.0)	0.06
MDS subtype
MDS w/o EB	1		1		1
MDS with EB	1.2 (1.1–1.4)	<0.001	1.9 (1.4–2.4)	<0.001	2.3 (1.3–4.0)	0.003
sAML	1.4 (1.2–1.5)	<0.001	2.1 (1.6–2.8)	<0.001	2.0 (1.2–3.6)	0.01
Donor match
HLA-identical sibling	1		1		1
Other donor	1.2 (1.1–1.3)	<0.001	1.1 (0.9–1.3)	0.3	1.1 (0.8–1.6)	0.5
Conditioning
Myeloablative	1		1		1
Reduced intensity	0.9 (0.9–1.0)	0.1	0.8 (0.7–1.0)	0.02	0.8 (0.5–1.1)	0.2
Previous relapse	NA		5.1 (4.2–6.1)	<0.001	5.0 (3.5–7.2)	<0.001

Cox models for excess mortality in defined time periods for patients alive at different landmarks.

LM landmark, HR hazard ratio, CI confidence interval, NA not applicable. Patients with missing information for conditioning were kept in the analysis in a separate category (not shown)